Izoprinozin

General characteristics. Structure:

Active agent: Inosine Pranobeks (Izoprinozin) - 500 mg; Excipients: Mannitolum, starch wheat, povidone, magnesium stearate.
Description: Oblong tablets of a biconvex form of white or almost white color with a light amine smell, with risky on one party.

Pharmacological properties:

Izoprinozin - synthetic complex derivative purine, having the immunostimulating activity and nonspecific antiviral action. Recovers functions of lymphocytes in the conditions of an immunosuppression, raises a blastogenesis in population of monocytic cells, stimulates an expression of membrane receptors on surface T-helperov, prevents decrease of the activity of lymphocytic cells under the influence of glucocorticosteroids, normalizes inclusion of thymidine in them. Izoprinozin exerts the stimulating impact on activity of cytotoxic T lymphocytes and natural killers, functions of T-suppressors and T-helperov, raises products of immunoglobulin (Ig) G, interferon - gamma, interleykin (IL)-1 and IL-2, reduces formation of pro-inflammatory cytokines - SILT-4 and SILT-10, exponentiates a chemotaxis of neutrophils, monocytes and macrophages. Drug shows antiviral activity of in vivo concerning the Herpes simplex viruses, a cytomegalovirus and a virus of measles, a virus of the T-cellular lymphoma of the person type III, poliomyelitis viruses, flu A and B, the ESNO-virus (an enterotsitopatogenny virus of the person), an entsefalomiokardit and horse encephalitis. The mechanism of antiviral action of Izoprinozin is connected with inhibition of virus RNA and the enzyme of a digidropteroatsintetaza participating in replication of some viruses strengthens the synthesis of MRNK of lymphocytes suppressed by viruses that is followed by suppression of biosynthesis of virus RNA and broadcast of virus proteins, raises products lymphocytes of the interferon having antiviral properties - an alpha and scale. At the combined appointment strengthens effect of interferon alpha, antiviral means of an acyclovir and zidovudine.

Pharmacokinetics. After intake drug is well soaked up from digestive tract. The maximum concentration of ingredients in a blood plasma is defined in 1-2 hours.

Quickly is exposed to metabolism and it is allocated through kidneys. It is metabolized to similarly endogenous purine nucleotides with formation of uric acid. N-N-dimethylamino-2-propranolon para-acetamidobenzoate - to au acylglucuronide is metabolized to N-oxide, and. Cumulation of drug in an organism is not revealed. The elimination half-life makes 3,5 hours for N-N-dimethylamino-2-propranolona and 50 minutes - for para-acetamidobenzoate. Elimination of drug and its metabolites comes from an organism within 24-48 hours.

Indications to use:

- Treatment of flu and other SARS;
- the infections caused by the Herpes simplex virus of the 1st, 2nd, 3rd and 4th types: genital and labial herpes, a herpetic keratitis, shingles, chicken pox, the infectious mononucleosis caused by Epstein-Barre's virus;
- Cytomegaloviral infection;
- measles of a heavy current;
- human papillomavirus infection: throat papillomas / phonatory bands (fibrous type), a human papillomavirus infection of genitalias at men and women, warts;
- contagious mollusk.

Route of administration and doses:

Pill is taken inside after food, washing down with a small amount of water.

The recommended dose to adults and children from 3 years (body weight from 15-20 kg) makes 50 mg/kg a day, divided into 3-4 receptions. The adult - on 6-8 tablets a day, to children - on 1/2 tablets on 5 kg/body weight a day. At severe forms of infectious diseases the dose can be increased individually to 100 mg/kg of body weight a day divided into 4-6 receptions. The maximum daily dose for adult 3-4 g/day, for children – 50 mg/kg/days.

Treatment duration:

Acute diseases: treatment duration at adults and children usually from 5 to 14 days. Treatment needs to be continued until disappearance of clinical symptoms and within 2 more days already in the absence of symptoms. If necessary duration of treatment can be increased individually under control of the doctor.

At chronic recurrent diseases at adults and children treatment needs to be continued by several courses for 5-10 days with a break in reception in 8 days.

For carrying out a maintenance therapy the dose can be lowered to 500-1000 mg a day (1-2 tablets) within 30 days.

At a herpes infection to adults and children appoint within 5-10 days before disappearance of symptoms of a disease, during the asymptomatic period - on 1 tablet 2 times a day within 30 days for reduction of number of a recurrence.

At a human papillomavirus infection the adult drug is appointed on 2 tablets by 3 times a day, to children - on 1/2. tablets on 5 kg/body weight a day in 3-4 receptions within 14-28 days in the form of monotherapy.

At recurrent sharp-pointed condylomas the adult drug is appointed on 2 tablets by 3 times, to children - on 1/2 tablets to 5 kg/body weight a day in 3-4 receptions a day either as monotherapy or in a combination with surgical treatment within 14-28 days, further with triple repetition of the specified bucketed course in 1 month. At a dysplasia of the neck of uterus associated with a virus of papilloma of the person appoint 2 tablets 3 times a day within 10 days, further conduct 2-3 similar courses at an interval of 10-14 days.

Features of use:

After 2 weeks of use of Izoprinozin it is necessary to carry out control of concentration of uric acid in blood serum and urine.

At long reception after 4 weeks of use it is reasonable to carry out every month control of functions of a liver and kidneys (activity of transaminases in a blood plasma, creatinine, uric acid).

It is necessary to control the level of uric acid in blood serum at purpose of an izoprinozin in combination with the drugs increasing the level of uric acid of an ilipreparatama, breaking function of kidneys.

Influence on ability of control of vehicles and other mechanisms. There are no special contraindications.

Side effects:

Frequency of development of side effects after use of drug is classified according to WHO recommendations.

Often:> =1%i <10%.

Sometimes:> =0,1% and <1%.

From digestive tract: often - nausea, vomiting, pain in epigastriums, sometimes - diarrhea, a lock.

From a liver and biliary tract: often - temporary increase in activity of transaminases and an alkaline phosphatase in a blood plasma, increase in concentration of urea in a blood plasma.

From skin and a hypodermic fatty tissue: often - an itch.

From a nervous system: often - a headache, dizziness, weakness; sometimes - drowsiness, sleeplessness.

From an urinary system: sometimes - a polyuria.

From a musculoskeletal system and connecting fabric: often - a joint pain, an exacerbation of gout.

Interaction with other medicines:

Immunodepressants can reduce efficiency of effect of drug. Inhibitors of a xanthineoxidase and uricosuric means (including diuretics) can promote risk of increase in level of uric acid in blood serum of the patients accepting Izoprinozin.

Contraindications:

- hypersensitivity to drug components;
- gout;
- urolithiasis;
- arrhythmias;
- chronic renal failure;
- children's age up to 3 years (the body weight is up to 15-20 kg).

Use of drug during pregnancy and a lactation. It is not recommended to use drug during pregnancy and during feeding by a breast as safety of use was not investigated.

Overdose:

It is not described.

Storage conditions:

Period of validity of 5 years. Not to use after the term specified on packaging. List B. To store at a temperature not above +25 °C in the dry, protected from light place. To store in the place, unavailable to children.

Issue conditions:

According to the recipe

Packaging:

Tablets 500 mg.10 tablets in the PVH/PVDH blister and aluminum foil. 2, 3 or 5 blisters in a pack cardboard together with the application instruction.